PVX-410 utilizes four peptide antigens targeting X-Box Binding protein 1, CD138, and SLAMF7, each of which were demonstrated to induce a myeloma-specific T cell response [169,170]. This evidence concerns the gene SDC1 and plasma cell myeloma.